アクセス数 : ?
ダウンロード数 : ?
ID 115523
著者
Sato, Aya Tokushima University
Shono, Kenji Tokushima University
Kitazato, Keiko Tokushima University
Matsuzaki, Kazuhito Tokushima University
Sumi, Akiko Tokushima University
Saya, Hideyuki Keio University
Sampetrean, Oltea Keio University
キーワード
COX-2
Low-grade glioma
Akt
Survivin
ID3
資料タイプ
学術雑誌論文
抄録
Approximately half of surgically-treated patients with low-grade-glioma (LGG) suffer recurrence or metastasis. Currently there is no effective drug treatment. While the selective COX-2 inhibitor celecoxib showed anti-neoplastic activity against several malignant tumors, its effects against LGG remain to be elucidated. Ours is the first report that the expression level of COX-2 in brain tissue samples from patients with LGG and in LGG cell lines is higher than in the non-neoplastic region and in normal brain cells. We found that celecoxib attenuated LGG cell proliferation in a dose-dependent manner. It inhibited the generation of prostaglandin E2 and induced apoptosis and cell-cycle arrest. We also show that celecoxib hampered the activation of the Akt/survivin- and the Akt/ID3 pathway in LGGs. These findings suggest that celecoxib may have a promising therapeutic potential and that the early treatment of LGG patients with the drug may be beneficial.
掲載誌名
Journal of Neuro-Oncology
ISSN
0167594X
15737373
cat書誌ID
AA10633712
出版者
Springer Nature
132
2
開始ページ
231
終了ページ
238
発行日
2017-03-10
備考
著者英表記誤記あり (誤)Shinji Nagahirao →(正)Shinji Nagahiro
権利情報
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
病院